---
title: "Insilico drops 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305596922.md"
description: "Insilico fell 6.03% to HK$35.54. Down 6.47% over five sessions and down 32.88% over six months."
datetime: "2026-11-16T01:40:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305596922.md)
  - [en](https://longbridge.com/en/news/305596922.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305596922.md)
generator: "portal-rs"
---

# Insilico drops 6%

Insilico (3696.HK) fell more than **6%** in Hong Kong trading, last at **HK$35.54**.

The stock is down 6.47% over the past five sessions and down 32.88% over the past six months. It sits 56.07% below its 52-week high of HK$80.90. Volume was 2.91 times its average.

The Hang Seng Index is down 2.98% over the past five sessions and down 7.45% year to date.

The life sciences tools and services industry index fell 2.2% over the same period.

The company announced plans to invest about 303 million yuan to establish a biomedical private equity fund with a total size of 1.01 billion yuan. The fund will primarily target growth-stage companies in biomedicine, life sciences and artificial intelligence, has a 10-year duration and will not be consolidated into the group's accounts.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)

## Related News & Research

- [Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery](https://longbridge.com/en/news/305433887.md)
- [INSILICO Plans Share Buyback of Up to HKD500M](https://longbridge.com/en/news/303654455.md)
- [Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma Trial](https://longbridge.com/en/news/303086760.md)
- [InSilico Medicine Hits Early AI Drug Discovery Milestone in Servier Collaboration](https://longbridge.com/en/news/302341377.md)
- [Chainfir Capital says AI drug deal headlines mask reliance on uncertain milestone payments](https://longbridge.com/en/news/302495363.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**